| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | ubiquitin protein ligase activity | 4.13e-05 | 372 | 35 | 6 | GO:0061630 | |
| GeneOntologyMolecularFunction | histone H2A ubiquitin ligase activity | 4.46e-05 | 6 | 35 | 2 | GO:0141053 | |
| GeneOntologyMolecularFunction | ubiquitin-like protein ligase activity | 6.01e-05 | 398 | 35 | 6 | GO:0061659 | |
| GeneOntologyMolecularFunction | L-leucine binding | 6.23e-05 | 7 | 35 | 2 | GO:0070728 | |
| GeneOntologyMolecularFunction | ubiquitin-protein transferase activity | 1.55e-04 | 473 | 35 | 6 | GO:0004842 | |
| GeneOntologyMolecularFunction | histone ubiquitin ligase activity | 1.95e-04 | 12 | 35 | 2 | GO:0140852 | |
| GeneOntologyMolecularFunction | ubiquitin-like protein transferase activity | 2.38e-04 | 512 | 35 | 6 | GO:0019787 | |
| GeneOntologyMolecularFunction | aminoacyltransferase activity | 2.92e-04 | 532 | 35 | 6 | GO:0016755 | |
| GeneOntologyMolecularFunction | acyltransferase activity | 2.08e-03 | 775 | 35 | 6 | GO:0016746 | |
| GeneOntologyMolecularFunction | protein kinase binding | 3.76e-03 | 873 | 35 | 6 | GO:0019901 | |
| GeneOntologyBiologicalProcess | ubiquitin-dependent protein catabolic process via the N-end rule pathway | 1.67e-05 | 4 | 35 | 2 | GO:0071596 | |
| Domain | ClpS_core | 3.41e-06 | 2 | 35 | 2 | IPR003769 | |
| Domain | ClpS | 3.41e-06 | 2 | 35 | 2 | PF02617 | |
| Domain | - | 1.02e-05 | 3 | 35 | 2 | 3.30.1390.10 | |
| Domain | Ribosomal_L7/12_C/ClpS-like | 1.02e-05 | 3 | 35 | 2 | IPR014719 | |
| Domain | ZF_RING_1 | 1.51e-05 | 291 | 35 | 6 | PS00518 | |
| Domain | ZF_RING_2 | 1.72e-05 | 298 | 35 | 6 | PS50089 | |
| Domain | Znf_RING | 2.86e-05 | 326 | 35 | 6 | IPR001841 | |
| Domain | RDM | 3.40e-05 | 5 | 35 | 2 | PF11002 | |
| Domain | RDM_domain_RFPL | 3.40e-05 | 5 | 35 | 2 | IPR022723 | |
| Domain | zf-UBR | 7.12e-05 | 7 | 35 | 2 | PF02207 | |
| Domain | Znf_UBR | 7.12e-05 | 7 | 35 | 2 | IPR003126 | |
| Domain | ZnF_UBR1 | 7.12e-05 | 7 | 35 | 2 | SM00396 | |
| Domain | ZF_UBR | 7.12e-05 | 7 | 35 | 2 | PS51157 | |
| Domain | - | 1.68e-04 | 449 | 35 | 6 | 3.30.40.10 | |
| Domain | Znf_RING/FYVE/PHD | 1.89e-04 | 459 | 35 | 6 | IPR013083 | |
| Domain | RING | 2.44e-04 | 305 | 35 | 5 | SM00184 | |
| Domain | WH1 | 2.63e-04 | 13 | 35 | 2 | PS50229 | |
| Domain | PRY | 2.80e-03 | 42 | 35 | 2 | PF13765 | |
| Domain | PRY | 3.65e-03 | 48 | 35 | 2 | SM00589 | |
| Domain | PRY | 3.65e-03 | 48 | 35 | 2 | IPR006574 | |
| Domain | Butyrophylin | 7.61e-03 | 70 | 35 | 2 | IPR003879 | |
| Domain | ConA-like_dom | 7.90e-03 | 219 | 35 | 3 | IPR013320 | |
| Domain | zf-C3HC4 | 8.30e-03 | 223 | 35 | 3 | PF00097 | |
| Domain | SPRY | 1.16e-02 | 87 | 35 | 2 | SM00449 | |
| Pathway | REACTOME_IRF3_MEDIATED_INDUCTION_OF_TYPE_I_IFN | 3.01e-05 | 5 | 25 | 2 | MM14942 | |
| Pathway | REACTOME_IRF3_MEDIATED_ACTIVATION_OF_TYPE_1_IFN | 3.01e-05 | 5 | 25 | 2 | M26979 | |
| Pathway | REACTOME_STING_MEDIATED_INDUCTION_OF_HOST_IMMUNE_RESPONSES | 6.31e-05 | 7 | 25 | 2 | MM14706 | |
| Pathway | REACTOME_REGULATION_OF_INNATE_IMMUNE_RESPONSES_TO_CYTOSOLIC_DNA | 2.33e-04 | 13 | 25 | 2 | MM14931 | |
| Pathway | REACTOME_IRF3_MEDIATED_INDUCTION_OF_TYPE_I_IFN | 2.33e-04 | 13 | 25 | 2 | M27240 | |
| Pathway | REACTOME_REGULATION_OF_INNATE_IMMUNE_RESPONSES_TO_CYTOSOLIC_DNA | 3.13e-04 | 15 | 25 | 2 | M27229 | |
| Pathway | REACTOME_STING_MEDIATED_INDUCTION_OF_HOST_IMMUNE_RESPONSES | 3.57e-04 | 16 | 25 | 2 | M27045 | |
| Pathway | REACTOME_ZBP1_DAI_MEDIATED_INDUCTION_OF_TYPE_I_IFNS | 6.21e-04 | 21 | 25 | 2 | M26978 | |
| Pathway | REACTOME_CYTOSOLIC_SENSORS_OF_PATHOGEN_ASSOCIATED_DNA | 1.45e-03 | 32 | 25 | 2 | MM14707 | |
| Pubmed | Bound Waters Mediate Binding of Diverse Substrates to a Ubiquitin Ligase. | 1.04e-06 | 2 | 36 | 2 | 28392261 | |
| Pubmed | Role of N-end rule ubiquitin ligases UBR1 and UBR2 in regulating the leucine-mTOR signaling pathway. | 1.04e-06 | 2 | 36 | 2 | 20298436 | |
| Pubmed | Structural basis of substrate recognition and specificity in the N-end rule pathway. | 1.04e-06 | 2 | 36 | 2 | 20835242 | |
| Pubmed | 1.04e-06 | 2 | 36 | 2 | 16606826 | ||
| Pubmed | 1.04e-06 | 2 | 36 | 2 | 16311597 | ||
| Pubmed | 1.04e-06 | 2 | 36 | 2 | 15548684 | ||
| Pubmed | Identification of Ubr1 as an amino acid sensor of steatosis in liver and muscle. | 3.12e-06 | 3 | 36 | 2 | 37057345 | |
| Pubmed | 3.12e-06 | 3 | 36 | 2 | 26674655 | ||
| Pubmed | 3.12e-06 | 3 | 36 | 2 | 15317757 | ||
| Pubmed | Evolutionary forces shape the human RFPL1,2,3 genes toward a role in neocortex development. | 3.12e-06 | 3 | 36 | 2 | 18656177 | |
| Pubmed | 6.24e-06 | 4 | 36 | 2 | 14585983 | ||
| Pubmed | The ATF3 Transcription Factor Is a Short-Lived Substrate of the Arg/N-Degron Pathway. | 6.24e-06 | 4 | 36 | 2 | 32692156 | |
| Pubmed | 6.24e-06 | 4 | 36 | 2 | 22388039 | ||
| Pubmed | An essential role of N-terminal arginylation in cardiovascular development. | 6.24e-06 | 4 | 36 | 2 | 12098698 | |
| Pubmed | 6.24e-06 | 4 | 36 | 2 | 27692986 | ||
| Pubmed | 6.24e-06 | 4 | 36 | 2 | 26407194 | ||
| Pubmed | A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons. | 6.24e-06 | 4 | 36 | 2 | 16055722 | |
| Pubmed | 6.24e-06 | 4 | 36 | 2 | 11689692 | ||
| Pubmed | The N-end rule pathway counteracts cell death by destroying proapoptotic protein fragments. | 6.24e-06 | 4 | 36 | 2 | 22670058 | |
| Pubmed | The substrate recognition domains of the N-end rule pathway. | 6.24e-06 | 4 | 36 | 2 | 19008229 | |
| Pubmed | 1.04e-05 | 5 | 36 | 2 | 10508838 | ||
| Pubmed | 1.04e-05 | 5 | 36 | 2 | 11850190 | ||
| Pubmed | 1.56e-05 | 6 | 36 | 2 | 10805755 | ||
| Pubmed | Five enzymes of the Arg/N-degron pathway form a targeting complex: The concept of superchanneling. | 1.56e-05 | 6 | 36 | 2 | 32366662 | |
| Pubmed | 2.18e-05 | 7 | 36 | 2 | 21816346 | ||
| Pubmed | RFPL4 interacts with oocyte proteins of the ubiquitin-proteasome degradation pathway. | 2.91e-05 | 8 | 36 | 2 | 12525704 | |
| Pubmed | Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation. | 3.73e-05 | 9 | 36 | 2 | 17855541 | |
| Pubmed | HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. | 6.83e-05 | 12 | 36 | 2 | 17360488 | |
| Pubmed | Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity. | 1.32e-04 | 95 | 36 | 3 | 29643511 | |
| Pubmed | 2.38e-04 | 22 | 36 | 2 | 33304758 | ||
| Pubmed | 2.83e-04 | 24 | 36 | 2 | 22157746 | ||
| Pubmed | ELAVL2-directed RNA regulatory network drives the formation of quiescent primordial follicles. | 4.75e-04 | 31 | 36 | 2 | 31657143 | |
| Pubmed | 5.39e-04 | 33 | 36 | 2 | 25582440 | ||
| Pubmed | 5.72e-04 | 34 | 36 | 2 | 25505242 | ||
| Pubmed | Web-based, participant-driven studies yield novel genetic associations for common traits. | 5.72e-04 | 34 | 36 | 2 | 20585627 | |
| Pubmed | NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression. | 6.78e-04 | 37 | 36 | 2 | 15326356 | |
| Interaction | RFPL2 interactions | 7.22e-06 | 22 | 35 | 3 | int:RFPL2 | |
| Interaction | WNT10A interactions | 3.58e-05 | 37 | 35 | 3 | int:WNT10A | |
| Interaction | RFPL1 interactions | 4.38e-05 | 6 | 35 | 2 | int:RFPL1 | |
| Interaction | NLRP4 interactions | 8.15e-05 | 8 | 35 | 2 | int:NLRP4 | |
| Interaction | MFAP5 interactions | 1.00e-04 | 52 | 35 | 3 | int:MFAP5 | |
| Interaction | RASL10B interactions | 1.25e-04 | 56 | 35 | 3 | int:RASL10B | |
| Cytoband | 16q24.3 | 7.73e-04 | 52 | 36 | 2 | 16q24.3 | |
| GeneFamily | Ubiquitin protein ligase E3 component n-recognins | 3.84e-05 | 7 | 25 | 2 | 785 | |
| Drug | Baclofen (R,S) [1134-47-0]; Down 200; 18.8uM; PC3; HT_HG-U133A | 5.12e-07 | 197 | 35 | 6 | 6313_DN | |
| Disease | Frontotemporal Lobar Degeneration | 3.03e-05 | 7 | 36 | 2 | C0751072 | |
| Disease | non-alcoholic fatty liver disease (implicated_via_orthology) | 8.88e-04 | 36 | 36 | 2 | DOID:0080208 (implicated_via_orthology) | |
| Disease | atherosclerosis (is_marker_for) | 9.38e-04 | 37 | 36 | 2 | DOID:1936 (is_marker_for) | |
| Disease | Metastatic melanoma | 1.99e-03 | 54 | 36 | 2 | C0278883 | |
| Disease | JT interval | 3.41e-03 | 248 | 36 | 3 | EFO_0007885 | |
| Disease | depressive symptom measurement, response to antidepressant | 5.19e-03 | 88 | 36 | 2 | EFO_0007006, GO_0036276 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| MEVSCPDGYTCCRLQ | 286 | P28799 | |
| CELMGTSLYAPEVCN | 741 | Q6JQN1 | |
| HYMCDILPLLECACT | 176 | Q15620 | |
| EPCDTVGIAYLSGMC | 446 | Q8TE59 | |
| CIMDVIGCLEYDPAL | 216 | Q6IN85 | |
| SPMYCFICCLALSDL | 71 | Q01726 | |
| SCDVMLEPGEYAVVC | 881 | O75808 | |
| TFCGTIEYCAPEVLM | 1161 | Q96RG2 | |
| ECHCPLGYAGVTCEM | 131 | Q5IJ48 | |
| ICPQGYTCCTSEMEE | 61 | P35052 | |
| SMACCIYVSELVGPR | 116 | O95528 | |
| MPTCLLCVCLSGSVY | 91 | P20774 | |
| CEALCSPDTVLVYLM | 771 | Q96MN2 | |
| IEDLSCVSCMPYLLE | 161 | Q96M69 | |
| EPQGLMYCLRCTCSE | 51 | Q6WN34 | |
| LCSGPCEMAEQRFCV | 81 | P49916 | |
| MTDAVVIPCCGNSYC | 266 | Q7Z6E9 | |
| GVCTQAPCYCIIMEY | 221 | O43283 | |
| FTCSLLIVGMCCVSP | 16 | A0A1B0GTK4 | |
| YLEKPMSLECGCAVC | 46 | O75677 | |
| DVLMCTACVPLTLAY | 106 | P49683 | |
| VPMANCSLYRSCGDC | 521 | Q9NPR2 | |
| CIETIMACSPCEGLY | 71 | Q8IZR5 | |
| RGCDNMCSYCIVPFT | 256 | Q96SZ6 | |
| TLPELIGIMDTCFCC | 101 | Q5VZE5 | |
| ALVALSFIVPCMCCY | 406 | Q7Z699 | |
| TSAQPFLCCLCGMIF | 876 | O15015 | |
| AIDPTCVLCMDCFQD | 116 | Q8IWV7 | |
| YLEKPMSLECGCTVC | 46 | O75679 | |
| DAIPSLSECQCGICM | 6 | Q8IYW5 | |
| CGEIMGCSFLNCYIT | 121 | Q9H7R0 | |
| PPSMEYCVLLFCCCI | 901 | Q8TCN5 | |
| CSPCILLYGMTLCCL | 466 | Q92508 | |
| AVDPTCVLCMECFLG | 116 | Q8IWV8 | |
| CYELTGEPLVCSMEG | 306 | Q9UI38 | |
| MEFCPCGSLYTVLEE | 86 | Q9UHD2 |